CYP cynata therapeutics limited

Ann: Encouraging Initial Data from CYP-006TK DFU Trial, page-40

  1. 16 Posts.
    lightbulb Created with Sketch. 4
    I fail to see how an adverse event could occur. The application is basic wound care with a stem cell based medication being applied.

    stem cells are naturally occuring in the body and we experience a gradual decline in volume as we age.

    stem cells have been used for years in various applications almost exclusively by the elites of the worlds - some athletes have even opted for stem cell infusions over surgey with fantastic results ie no scaring or mobilty issues that surgery would ultimatly cause.

    we are getting to the exciting end of science, CYP it seems has cracked the code and this will offer tremendous benefit to many people world wide. Very valuable IP

    Congratulations to all holders.

    Best of all this is just one product of many in the pipeline.



 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
16.5¢
Change
0.000(0.00%)
Mkt cap ! $37.28M
Open High Low Value Volume
16.0¢ 16.5¢ 16.0¢ $10.82K 65.84K

Buyers (Bids)

No. Vol. Price($)
2 4450 16.5¢
 

Sellers (Offers)

Price($) Vol. No.
17.0¢ 88474 2
View Market Depth
Last trade - 15.32pm 20/06/2025 (20 minute delay) ?
CYP (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.